MIRA submits IND for Ketamir-2 (neuropathic pain) to FDA; Phase I expected Q1 2025

MIRA PHARMACEUTICALS, INC.

IND submitted to FDA on Dec 19, 2024 for Ketamir-2, a novel oral ketamine analog.
Phase I clinical trials expected to start Q1 2025; Phase IIa planned for late 2025.
Preclinical data showed full pain reversal with no adverse safety findings.
Ketamir-2 targets unmet needs in neurological disorders and neuropathic pain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.